Introduction
Increasing attention has been focused on using antiplatelet agents to prevent and treat peripheral vascular disease (PVD). While these drugs may improve the symptoms and natural history of PVD, they also have proven efficacy in prev~nting and treating co-morbid cardiovascular disease involving the coronary and cerebral circulations. Antiplatelet agents also help maintain vascular patency after surgical revascularization and angioplasty. Because only a limited number of adequate pharmacological trials have been conducted, the role of drug therapy in preventing and treating PVD continues to evolve.
Epidemiology and natural history of PVD
The incidence of PVD increases with age and is more common in males than in females. Risk factors include cigarette smoking, diabetes, hypertension and hyperlipidaemia.l-e The most common symptom of PVD is intermittent claudication. Its prevalence by the standardized Rose questionnaire in one review increased from 1.1 % in patients under 40 years of age to 5.2% in patients over age 70. 3 These rates of claudication, however, underestimate the true prevalence of PVD. While 1.7% of women and 2.2% of men in another study population had intermittent claudication by history, 11.7% of the population had evidence of large vessel PVD by Doppler ultrasound and segmental blood pressures.s
Although the natural history of PVD itself is rather benign, the overall prognosis for patients with this disease is dictated by the high frequency of co-morbid coronary artery and cerebrovascular disease. The life expectancy of patients with PVD is approximately ten years less than that of the general population." Criqui et al. showed that, after adjustment for cardiovascular risk factors, patients with large vessel PVD have relative risks of death from all causes and death from cardiovascular disease of 3.1 and 5.9, respectively, when compared with control subjects over ten years.o Moreover, the Whitehall study not only demonstrated that claudication was associated with increased mortality from coronary artery and cerebrovascular disease, but also that this increased risk was independent of other risk factors including hypertension, hypercholesterolaemia, smoking and glucose intolerance." Thus, antiplatelet agents may have their greatest impact on patients with intermittent claudication by limiting thrombotic cardiovascular disease at other, more critical, sites.
Platelet function and the pathogenesis ofPVD
Atherosclerosis in peripheral arteries can lead to chronic obstruction manifested clinically as intermittent claudication, ulceration, or gangrene. Additionally, thrombosis may create acute occlusion and limb-threatening ischaemia when it occurs either in situ or at a distance with subsequent peripheral embolization. Platelets, through their involvement in these processes, are central to the development of obstructive arterial disease.
Although platelet function appears to have a minimal role in the initial development of atherosclerotic plaques, it may accelerate plaque growth.f Thrombosis at sites of atherosclerosis may stimulate proliferation of smooth muscle cells via growth factors, such as platelet-derived growth factor (PDGF), and lead to increased synthesis of extracellular elements within the plaque." In addition, mural thrombi that form on the surface of plaques may organize within the lesion and increase plaque size.?
Platelet activation, which leads to configurational change, adhesion, aggregation and secretion, is central to thrombosis.l'' Sites of vascular injury at atherosclerotic lesions initiateadhesion and activation by exposing thrombogenic compounds such as collagen and thrombin (figure 1),11 and by generating shear forces that act on platelets.!? During activation, platelets also secrete adenosine diphosphate (ADP) and serotonin from their granules. These compounds further stimulate activation ( Figure  1 ).11 .12 In the setting of activation, thromboxane A 2 (TxA 2 ) , which also activates platelets ( Figure  1 ),11 is synthesized from arachidonic acid (Figure 2) . 13 Phospholipase A z releases arachidonic acid from platelet membrane phospholipids. The platelet eyclo-oxygenase enzyme, prostaglandin G/H synthase, then catalyses the conversion of arachidonic acid to prostaglandins G z and Hz (PGG z and PGH z ). Ultimately, these cyclic endoperoxide intermediates are converted by thromboxane synthase to TxA z, a potent platelet activator and vasoconstrictor that acts through binding to specific membrane receptors. 14 This biochemical activation pathway within platelets is counter-regulated by a platelet inhibition pathway within the vascular endothelium which also involves the generation of PGG 2 and PGH 2 . However, in the vascular endothelium, these compounds are converted by prostacyclin synthase to prostacyclin (PGI 2 ) , a platelet inhibitor and vasodilator ( Figure 2 ).10.13 PGI 2 acts through stimulating adenyl cyclase, the enzyme that synthesizes cyclic AMP (cAMP). Increased platelet cAMP levels inhibit platelet function. Of note, the platelet and endothelial pathways are linked because PGG 2 and PGH 2 generated in platelets may be released and serve as substrate for prostacyclin synthase in the vascular endothelium (figure 2). 10.13 Following activation, platelet aggregation occurs and is central to thrombus formation ( Figure 1 ).11 With activation, a conformational change takes place in the platelet membrane's glycoprotein lIb-IlIa complex (GP lIb-IlIa) which allows it to act as a receptor for macromolecules such as fibrinogen, von Willebrand factor and fibronectin. The subsequent binding of the GP lIb-IlIa receptors to these macromolecules results in platelet aggregation. 10.11 
Clinical trials and drug therapies for PVD
Pharmacological therapy for PVD has been difficult to study clinically because of the disease's variable natural history and the dearth of simple, valid and reliable measures to assess the disease, 15, 16 In addition, although small trials have focused on using anti platelet agents to treat claudication, there have been few large, randomized, double-blind, placebo-controlled trials to define clearly the efficacy of drug therapy.P With the growing evidence that platelet function is involved in the pathogenesis of PVD, clinical investigators have begun to focus more attention on the use of antiplatelet agents to treat this condition. Table  1 summarizes information on the mechanisms of action, dosing and adverse effects of the antiplatelet agents discussed below. Table 2 summarizes from available data some of the clinical settings in which antiplatelet therapy is likely to be beneficial.
Aspirin
Aspirin is the most extensively studied and commonly used antiplatelet agent. It is effective in the primary prevention of myocardial infarction'? and the prevention of cardiovascular events in patients with histories of cardiovascular disease.l'' Aspirin irreversibly inhibits the cyclo-oxygenase, prostaglandin G/H synthase, within platelets by acetylating serine residue number 529 near the active site of the enzyme ( Figure  3 ). 19 This action decreases platelet synthesis of TxA z and thus inhibits platelet activation and subsequent thrombosis.is.w Given that platelets are anucleate and unable to synthesize new prostaglandin GIH synthase, aspirin inhibits the enzyme's function for the eight-to ten-day lifetime of the platelet. 19 While the dose of aspirin required for its antiplatelet effect has been debated, studies have shown that as little as 3D-50 mg per day of aspirin will completely inhibit platelet TxA z production within seven to ten days.t? Furthermore, alternate day dosing of aspirin has been shown to be effective in some studies, 17 The most commonly used doses in clinical trials, however, are 'medium dose' aspirin at 75-325 mg per day. 18 Establishment of the efficacy of lower dose aspirin is important because the major side effects of 19 Clinical trials have studied the use of aspirin to prevent and treat PVD as well as its co-morbid cardiovascular diseases. The US Physicians' Health Study (PHS) provided data on the primary prevention of peripheral vascular surgery in healthy physicians treated with 325 mg of aspirin every other day versus placebo.s? Chronic administration of aspirin reduced the need for peripheral arterial surgery. The risk of undergoing peripheral vascular surgery in the aspirin group versus the placebo group was decreased by 46% (p = 0.03).
In a subgroup analysis of 86 subjects who had a history of claudication without vascular surgery prior to entering the PHS, nine went on to have peripheral arterial surgery during the study. Of note, eight of these nine patients had been allocated to the placebo group and only one to the aspirin treatment group. This difference favouring aspirin in the prevention of peripheral vascular surgery in patients with claudication was statistically significant. However, aspirin did not affect the likelihood of developing new symptoms of claudication during the study period.s?
Perhaps the best rationale for using aspirin in patients with PVD is its documented efficacy in the prevention and treatment of cardiovascular events. In a meta-analysis of 174 randomized trials of antiplatelet therapy, the Antiplatelet Trialists' Collaboration showed that antiplatelet therapy has a significant protective effect against nonfatal myocardial infarction, nonfatal stroke and vascular death in high-risk patients with cardiovascular diseases.l'' Aspirin, in doses of 75-325 mg per day, was the most common agent tested, and there was no significant evidence that higher doses were more effective.
In a subgroup of high-risk patients which included among others those with a history of vascular surgery, peripheral angioplasty, or peripheral vascular disease, the percentage odds reductions versus controls were as follows: 32% for the risk of myocardial infarction, stroke, or vascular death; 32% for the risk of nonfatal myocardial infarction; 46% for the risk of nonfatal stroke; 20% for the risk of vascular death. All of these reduction were statistically significant. 18 With respect to treatment of PVD, only a few small studies have examined aspirin's ability to prevent disease progression. For example, Hess et al. randomized 240 patients to aspirin, aspirin plus dipyridamole, and placebo, and found that angiographic progression of lesions occurred less often in the aspirin plus dipyridamole group compared to aspirin alone or placebo.s! Of note, aspirin was not statistically significantly different from placebo although there was a trend toward less progression with aspirin alone. Also, at the time of randomization, the aspirin alone group had more stenosing lesions than the other two groups, possibly increasing the rate of progression in this group and explaining why no statistically significant difference from placebo was found. As with some other clinical trials, this study additionally failed to address more clinically relevant end-points such as symptoms, exercise capacity and the incidence of subsequent revascularization.
Dipyridamole
Dipyridamole has been proposed to act as an antiplatelet agent by three main mechanisms.P First, it may inhibit platelet phosphodiesterase, the enzyme that breaks down cAMP. Inhibition of this enzyme leads to increased levels of cAMP and platelet inhibition. Second, it may increase the synthesis and potentiate the effects of PGI 2. Finally, it may inhibit cellular uptake of adenosine, thereby increasing plasma concentrations of this platelet inhibitor and vasodilator. While 
Ticlopidine
Ticlopidine is a specific antiplateiet agent that has been relatively well studied in patients with PVD. Although its mechanism of action in vivo is not entirely clear, the drug appears to inhibit ADP-induced aggregation of platelets, possibly by interfering with the binding of macromolecules to the activated platelets' GP lIb-IlIa complex.>
The standard dose of ticlopidine for the treatment of PVD is 250 mg twice a day. The most serious adverse effects of this medication are neutropenia and agranulocytosis, which occur in 1-2% of patients and are reversible with discontinuation of the drug,26 This effect is typically seen between the third week and third month of therapy and, consequently, complete blood counts and white blood cell differentials should be performed every two weeks during the first A ntip latelet agents and peripheral vascular disease 115 three months of treatment and then subsequently with any sign of infection.w Other side-effects include diarrhoea in about 20% of patients, nausea, thrombocytopenia, pancytopenia, minor haemorrhagic complications such as epistaxis and ecchymoses, and skin rashes.P Early clinical trials studying ticlopidine showed that it may accelerate healing of ischaemic ulcers in patients with chronic PVD.27,28 In a randomized, controlled study of 193 patients with ischaemic ulcers, Katsumura et al. showed that treatment with ticlopidine significantly increased epithelialization and improved ulcer appearance compared with placebo.s" Additional randomized, double-blind, placebo-controlled trials have demonstrated an improvement in functional capacity of patients on ticlopidine by assessing walking distance and syrnptoms.P<"
The use of ticlopidine by patients with PVD has been shown to decrease the rate of associated cardiovascular events. In a meta-analysis, Boissel et al. demonstrated a statistically significant reduction in the rate of fatal and nonfatal cardiovascular events from 9% to 3% in patients with intermittent claudication treated with ticlopidine versus placebo.F In addition, the Swedish Ticlopidine Multicenter Study (STIMS) trial found a significant reduction in the rate of primary cardiovascular events (myocardial infarction, stroke and transient ischaemic attacks) with on-treatment analysis, and total mortality with intention-to-treat analysis in patients with claudication treated with ticlopidine.P More recently, a study conducted in Argentina showed that treatment with ticlopidine reduced the rate of both fatal and nonfatal cardiovascular events in patients with intermittent claudication.v' Of note, additional outcome data in this study revealed that treatment with ticlopidine significantly reduced the rate of vascular surgery compared with placebo.>
Ketanserin
Ketanserin is a selective serotonin (5-HT 2) receptor antagonist that inhibits serotonininduced platelet aggregation and vasoconstriction.P> The drug also possesses antihypertensive actions and haemorrheological effects, such as reducing blood viscosity and red blood cell rigidity.t! Because of these properties, it has been studied as a treatment for PVD and associated cardiovascular diseases.
While the results of early small trials on the use of ketanserin to treat intermittent claudication were conflicting,36,37 later studies have shown no benefit of the drug versus placebo. 38.39 The Prevention of Atherosclerotic Complications with Ketanserin (PACK) Trial Group conducted a large-scale, randomized, placebo-controlled trial to determine if ketanserin treatment would prevent death, myocardial infarction, stroke, or lower extremity amputation in patients with intermittent claudication.sc Unlike the data for aspirin and ticlopidine, ketanserin did not prevent such primary end-points. In fact, treatment with the drug was associated with increased mortality compared with placebo due to sudden death in the setting of ketanserin-induced QT interval prolongation in patients using potassium-lowering diuretics.s? A subgroup analysis from this trial showed that ketanserin did not increase pain-free treadmill walking time compared with placebo over one year of treatment.O Given these results, ketanserin does not confer benefits in the treat-mentofPVD.
I1oprost
The naturally occurring platelet inhibitor PGL, has limited clinical usefulness in treating thrornbotic disease because of its instability, requirement for parenteral administration, and hypotensive side effects.tv Iioprost, a chemically stable analogue of PGI 2, has been given in prolonged, intermittent infusions to treat PVD.42 Like PGI." this agent inhibits platelets by stimulating platelet adenyl cyclase and increasing levels of platelet cAMP. The drug has been studied most extensively in the treatment of chronic critical ischaemia, defined by ischaemic rest pain, gangrene, or ulceration in a setting of reduced perfusion pressures. In the Second European Consensus Document on Chronic Critical Leg Ischemia, placebo-controlled trials of iloprost were reviewed.ss Because there was some evidence of efficacy, its use was recommended for patients in whom mechanical revascularization could not be performed. However, like PGI 2, iloprost's clinical utility has been limited by its short duration of action and the need for intravenous administration.
Pentoxifylline
Pentoxifylline is the most extensively studied pharmacological agent for the treatment of PVD. Although its primary mechanism of action is through haemorrheological and not anti platelet effects, the drug may inhibit platelet aggregation and has a wide range of other actions which could be relevant to its use in PVD.44,4S Its antiplatelet activities appear to occur through stimulation of PGl z secretion by endothelial cells and elevation of platelet cAMP Ievels.ss Although some studies have demonstrated an improvement in mean pain-free and maximal walking distances in patients treated with pentoxifylline.f others have questioned the generalizability of these positive results to clinical practice.47
Other antiplatelet agents
Multiple other antiplatelet agents have been tested in the treatment of PVD. Some of these have included indobufen, a reversible cyclo-oxygenase inhibitor,4s-so picotamide, a thromboxane synthase inhibitor and TxA z receptor antagonist.s! and cilostazol, a platelet phosphodiesterase inhibitor.V Too few data are available on these agents to evaluate them fully at this time. However, these types of drugs and other antiplatelet agents such as omega-3 fatty acids and the newer GP IIb-Illa receptor inhibitors will undergo further investigation.
Antiplatelet agents and mechanical revascularization of PVD
Following infrainguinal peripheral artery revascularization, there is a high rate of reocclusion. In a study of bypass procedures; primary patency rates four years following infrainguinal bypass to infrapopliteal arteries were 49% and 12% for saphenous vein and polytetrafluoroethylene grafts, respectively. 53 The pathophysiology of occlusion after revascularization is linked to platelet function. Early thrombosis can occur due to exposure of thrombogenic surfaces or technical errors. In addition, restenosis at anastomotic sites may take place because of intimal hyperplasia of the adjacent native vessel. It is theorized that platelet release of PDGF is the stimulus for the smooth muscle cell proliferation that characterizes this process.> Finally, platelet activity induced by the artificial surfaces of prosthetic grafts is probably central to the high longer-term rate of prosthetic graft failure.
Several randomized, controlled studies have demonstrated that antiplatelet therapy with aspirin alone or aspirin plus dipyridamole in the setting of infrainguinal prosthetic bypass grafts leads to lower rates of reocclusion. S4-S6 Of note, one study showed no significant difference between aspirin plus dipyridamole compared with placebo when these agents were initiated postoperatively.57 These data, taken in the context of other studies including those on coronary artery bypass grafts, suggest that preoperative initiation of antiplatelet therapy is important in establishing therapeutic efficacy.
Although the use of anti platelet therapy in the setting of infrainguinal prosthetic grafts may increase patency rates, its use with vein grafts provides no clear benefit with respect to patency.58 In a randomized, double-blind study, McCollum et ai. compared aspirin plus dipyridamole with placebo in 549 patients who underwent femoropopliteal vein bypass surgery and found no statistically significant difference in patency rates between the two groups.w This study also examined the rate of cardiovascular events, including myocardial, infarction and stroke, over a mean follow-up period of 34 months in both groups. The rate of such events was significantly lower in the treatment group compared to the placebo group. Consequently, while antiplatelet therapy may not improve vein graft patency, it does appear to reduce the rate of myocardial infarction and stroke in these patients and is indicated for this purpose.ss
In recent years, percutaneous transluminal angioplasty (PTA) has been used increasingly for mechanical revascularization. While data have shown that platelets accumulate at PTA sites 60 and are likely to be central in acute thrombosis and reocclusion, their role in longer-term restenosis is not clear. To date, there are only a small number of trials studying the use of antiplatelet agents with PTA,61,62 Much of the data supporting their use has been generalized from studies conducted on percutaneous transluminal coronary angioplasty (PTCA).s8 In trials involving PTCA, initiation of antiplatelet therapy prior to angioplasty has been shown to reduce the rate of acute occlusion and myocardial infarction. however, it is unclear if generalization of data from coronary artery to peripheral artery angioplasty is appropriate.
Further evidence that antiplatelet therapy is useful to maintain vascular patency in the setting of peripheral revascularization is from the Antiplatelet Trialists' Collaboration metaanalysis.e> In their overview of 14 trials, which included a total of about 3000 patients with peripheral vascular disease or undergoing peripheral revascularization, they found that treatment with anti platelet agents for a mean duration of 19 months reduced the risk of occlusion from 25% in controls to 16%. This result corresponded to a prevention of vascular occlusion in 92 patients per 1000 treated with anti platelet therapy (2p < 0.00001).
Conclusions
There is growing evidence that antiplatelet agents such as aspirin and ticlopidine are effective in preventing and treating PVD. Furthermore, their clearest benefit in patients with PVD is probably their therapeutic impact on concomitant coronary and cerebrovascular disease. In addition, antiplatelet agents have been shown to prevent vascular reocclusion in the setting of revascularization with prosthetic bypass grafts.
Future clinical trials will more precisely establish the role of antiplatelet therapy in preventing and treating PVD, and will examine some of the novel antiplatelet agents that are currently being developed.
